Search clinical trials for: Resected

Total 262 results

Wu Wenming
NeoCura

Not yet recruiting

XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer

Pancreatic Cancer

China
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Australia, Taiwan, Brazil, Japan, Argentina
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

Lung Cancer | Non Small Cell Lung Cancer | Lung Adenocarcinoma | Small-cell Lung Cancer | Lung Squamous Cell Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
Medical College of Wisconsin

Recruiting

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence (PROTECT-PANC)

Pancreas Cancer

United States
Ruijin Hospital
Regend Therapeutics

Not yet recruiting

Follow-up Study of Autologous Transplantation of P63+ Lung Progenitor Cells for Treatment of Bronchiectasis

Bronchiectasis

China
Fudan University
Shanghai Regenelead Therapies Co., Ltd.

Not yet recruiting

Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Pancreatic Cancer

China
OHSU Knight Cancer Institute
Oregon Health and Science University; Kuni Foundation

Recruiting

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma

Clinical Stage IIA Cutaneous Melanoma AJCC v8

United States
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
UNICANCER
SOLTI Breast Cancer Research Group; Vall d'Hebron Institute of Oncology; MSD...

Not yet recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)

Triple-negative Breast Cancer
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms

Digestive System Neoplasms

China
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

Resectable Lung Non-Small Cell Carcinoma

United States
Genentech, Inc.
BioNTech SE

Recruiting

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003)

Adenocarcinoma, Pancreatic Ductal

United States
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Trevi Therapeutics

Recruiting

Refractory Chronic Cough Improvement Via NAL ER (RIVER) (RIVER)

Refractory Chronic Cough

Canada, United Kingdom
Centre Leon Berard

Recruiting

Study Comparing Negative Pressure Dressing vs Conventional in Patients With Resected STS After Radiotherapy (TPN-RAD)

Soft Tissue Sarcoma

France
Shanghai Pulmonary Hospital, Shanghai, China
Zunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...

Recruiting

Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma

Lung Adenocarcinoma | Whole Slide Image | Novel Grading System

China
Shanghai Pulmonary Hospital, Shanghai, China
Zunyi Medical College; Ningbo HwaMei Hospital, Zhejiang, China; The First Affiliated...

Recruiting

Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Spread Through Air Space | Visceral Pleural Invasion | Lymphovascular Invasion

China
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Italy, Spain, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Netherlands, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico, India
Rigshospitalet, Denmark

Not yet recruiting

3D Ultrasound, Specimen Examination by Surgeon, and MRI in Surgical Margin Assessment

Head and Neck Cancer | Squamous Cell Carcinoma | Tongue SCC

Denmark
Amal Therapeutics
Boehringer Ingelheim

Recruiting

A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)

Pancreatic Ductal Adenocarcinoma

United States, Switzerland
Peking Union Medical College Hospital

Recruiting

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer (MAP-02)

Pancreatic Cancer | Resectable Carcinoma

China
University Hospital, Toulouse

Recruiting

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse (MIRACLE)

Non-small Cell Lung Cancer Stage IIIA

France
Merck Sharp & Dohme LLC

Recruiting

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Melanoma

Poland, Canada, Australia, Israel, Chile, Korea, Republic of, New Zealand, Switzerland, United States, Argentina, Brazil, China, Turkey, South Africa, India, Austria, Germany, Spain, United Kingdom, Belgium, France, Italy, Sweden, Ire... and more
University of Kansas Medical Center
Targovax ASA

Not yet recruiting

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA)

Pancreas Cancer

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Melanoma

United States, Australia, Spain, United Kingdom, Canada, Brazil, Mexico, Germany, Ireland, South Africa, France, Israel, Georgia, Turkey, Italy, Poland, Chile, Argentina, Belgium, Czechia, Romania, Greece
Yongtao Han

Recruiting

RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY

the Records of Esophageal Cancer

China
Baptist Health South Florida
Blue Earth Diagnostics

Recruiting

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis (CONCORDANT)

Brain Cancer | Brain Metastases

United States
Hospices Civils de Lyon

Recruiting

Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma (Mel-ImmAdj)

Melanoma

France
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
National Cancer Centre, Singapore
National University Hospital, Singapore; Singapore General Hospital; Tan Tock... and other collaborators

Recruiting

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (EMPHASIS)

Hepatocellular Carcinoma

Singapore
BAIYONG SHEN
GeneCast Biotechnology Co., Ltd.

Not yet recruiting

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

Pancreatic Cancer Resectable

China
Oana Danciu
Novartis Pharmaceuticals

Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR)

HER2-negative Breast Cancer | Locoregional Recurrence | Hormone Receptor-positive Breast Cancer

United States
Guangdong Association of Clinical Trials

Recruiting

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD

Non Small Cell Lung Cancer

China
Rutgers, The State University of New Jersey

Recruiting

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Pancreatic Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Romania, Spain, Switzerland, Netherlands, Poland, Por...
John Neoptolemos
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Deutsches... and other collaborators

Not yet recruiting

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Pancreatic Ductal Adenocarcinoma

Sweden, Germany
The First Affiliated Hospital of Zhengzhou University
BeiGene

Recruiting

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC (Seagull)

NSCLC

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ETNT)

Esophageal Squamous Cell Carcinoma

China
University Hospital, Montpellier

Recruiting

Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis (LUNGDOC)

Nsclc

France
Tongji University

Recruiting

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma (ATHEM)

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
National Cancer Centre, Singapore
Nanyang Technological University; Duke-NUS Graduate Medical School; MiRXES Pte... and other collaborators

Recruiting

Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma (PROSECT)

Hepatocellular Carcinoma

Singapore
Medical College of Wisconsin

Recruiting

Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)

Resectable Head and Neck Squamous Cell Carcinoma

United States
Gruppo Oncologico del Nord-Ovest
Seagen Inc.; Servier; Foundation Medicine

Recruiting

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (ERASE-CRC)

Stage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon Cancer

Italy
Fudan University

Recruiting

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Gastric Cancer

China
Novartis Pharmaceuticals

Recruiting

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. (LEAD Melanoma)

Melanoma

Turkey
McGill University Health Centre/Research Institute...
Pulmonem Inc.

Recruiting

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (DAP-CORONA)

COVID-19

Canada, United States
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
BioNTech SE

Recruiting

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

Colorectal Cancer Stage II | Colorectal Cancer Stage III

United States, Spain, Germany, Belgium

Search clinical trials for: Resected

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations